Nanoparticulate contrast agents. In vivo diagnostics;Nanopartikelbasierte kontrastmittel. In-vivo-diagnostik

Onkologe

Volumn 13, Issue 10, 2007, Pages 931-938

  Glockl G ^a   Weitschies, W ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Contrast agent; Magnetic resonance imaging; Microbubbles; Superparamagnetic iron oxides; Ultrasound

Indexed keywords

CONTRAST MEDIUM; CRYSTALLIN; ECHOVIST; FERUMOXSIL; FS 069; IRON OXIDE; NANOPARTICLE; SHU 508; SONOVUE; SUPERPARAMAGNETIC IRON OXIDE; SUPRAVIST; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DRUG DESIGN; GAS; GERMANY; HUMAN; IN VIVO STUDY; LIVER DISEASE; MICROBUBBLE; NUCLEAR MAGNETIC RESONANCE IMAGING; SENSITIVITY AND SPECIFICITY; ULTRASOUND;

EID: 35949000155     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-007-1261-5     Document Type: Article

References (27)

1. Anzai Y (2004) Superparamagnetic iron oxide nanoparticles: nodal metastases and beyond. Top Magn Reson Imaging 15: 103-111
2. Atri M (2006) New technologies and directed agents for applications of cancer imaging. J Clin Oncol 24: 3299-3308
3. Bjørnerud A, Johansson LO, Ahlström HK (2001) Pre-clinical results with Clariscan™ (NC100150 Injection); experience from different disease models. MAGMA 12: 99-103
4. Büscher K, Helm CA, Groß C et al. (2004) Nanoparticle composition of a ferrofluid and its effects on the magnetic properties. Langmuir 20: 2435-2444
5. Correas JM, Bridal L, Lesavre A et al. (2001) Ultrasound contrast agents: properties, principles of action, tolerance, and artifacts. Eur Radiol 11: 1316-1328
6. Desai N, Trieu V, Yao Z et al. (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12: 1317-1324
7. Dietrich CF, Schreiber-Dietrich D, Schuessler G et al. (2007) Kontrastverstärkte Ultraschalluntersuchung der Leber - Aktueller Wissensstand. Dtsch Med Wochenschr 132: 1225-1231
8. Glöckl G, Hergt R, Zeisberger M et al. (2006) The effect of field parameters, nanoparticle properties and immobilization on the specific heating power in magnetic particle hyperthermia. J Phys Condens Matter 18: S2935-S2949
9. Grubnic S, Padhani AR, Revell PB et al. (1999) Comparative efficacy of and sequence choice for two oral contrast agents used during MR imaging. AJR Am J Roentgenol 173: 173-178
10. Hauff P, Fritzsch T, Reinhardt M et al. (1997) Delineation of experimental liver tumors in rabbits by a new ultrasound contrast agent and stimulated acoustic emission. Invest Radiol 32: 94-99
11. Helmberger T, Gregor M, Holzknecht N et al. (1999) Detektion und Charakterisierung fokaler Leberläsionen. Radiologe 39: 678-684
12. Herbay A von, Vogt C, Häussinger D (2003) Ultraschallkontrastmittel in der Diagnostik fokaler Leberläsionen. Onkologe 9: 247-262
13. Hoehn M, Küstermann E, Blunk J et al. (2002) Monitoring of implanted stem cell migration in vivo: a highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in rat. Proc Natl Acad Sci USA 99: 16267-16272
14. Ito A, Honda H, Kobayashi T (2006) Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of "heat-controlled necrosis" with heat shock protein expression. Cancer Immunol Immunother 55: 320-328
15. Johannsen M, Gneveckow U, Eckelt L et al. (2005) Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int J Hyperthermia 21: 637-647
16. Kaick G van, Muth H, Kaul A (1984) Comission of the European Communities. Radiation protection. The German thorotrast study. Office for Official Publications of the European Communities, Luxembourg
17. Müller M, Reimer P, Wiedermann D et al. (1998) T1-gewichtete dynamische MRT mit neuen superparamagnetischen Eisenoxidpartikeln (Resovist®): Ergebnisse einer Studie am Phantom sowie an 25 Patienten. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 168: 228-236
18. Quaia E (2007) Microbubble ultrasound contrast agents: an update. Eur Radiol 17: 1995-2008
19. Romanus E, Hückel M, Groß C et al. (2002) Magnetic nanoparticle relaxation measurement as a novel tool for in vivo diagnostics. J Mag Magn Mat 252: 387-389
20. Saksena MA, Saokar A, Harisinghani MG (2006) Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging. Eur J Radiol 58: 367-374
21. Schaffer BK, Linker C, Papisov M et al. (1993) MION-ASF: biokinetics of an MR receptor agent. Magn Reson Imaging 11: 411-417
22. Schick F (2007) Grundlagen der Magnetresonanztomographie. Radiologe [Suppl 1] 47: S7-S26
23. Seitz K (2005) Kontrastmittelsonographie bei Leberzellkarzinom und Lebermetastasen. Ultraschall Med 26: 267-269
24. Strobel D, Bernatik T (2006) Diagnostik bei fokalen Leberläsionen: Stellenwert der Kontrastmittelsonographie. Dtsch Arztebl 103: A789-A793
25. Trieu V, Desai N, Neil P et al. (2005) Treatment methods utilizing albumin-binding proteins as targets. Instituto Mexicano de la Propiedad Industrial, México, WO 2005117952
26. Will O, Purkayastha S, Chan C et al. (2005) Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol 7: 52-60
27. Yanagisawa K, Moriyasu F, Miyahara T et al. (2007) Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol 33: 318-325